Insulin GST is 5%, not 12%: why getting this right saves a diabetic ₹2,400 a year
Insulin sits on the GST concessional list at 5%, not the general medicine slab at 12%. Pharmacies still get this wrong. Here's why insulin is treated as concessional, the HSN code that applies, and how to spot the wrong rate.
Published · Jaanch
A typical Type 1 diabetic on insulin glargine spends about Rs 3,000 a month. Over a year, that's Rs 36,000. Over a working life, after adjusting nothing for inflation, well over Rs 10 lakh. So the difference between 5% GST and 12% GST is not academic. It's roughly Rs 210 a month, or Rs 2,500 a year, or just under Rs 1 lakh over a diabetic's working lifetime.
This is one of those niche but solid corners of Indian tax policy where the right thing has been done, but the implementation routinely gets it wrong. Insulin is at 5%. Most hospital pharmacies and retail pharmacies in India still bill it at 12%. Here's why, and how to spot it.
The GST schedule has three medicine slabs
When India moved to GST in 2017, the rate council had to slot every drug into one of the goods-rate schedules. The current shape:
- Schedule I — 5%. Reserved for "essential" categories. Insulin, oral rehydration salts, anti-tuberculosis drugs, anti-malarial drugs, certain anti-cancer drugs, life-saving drugs notified separately by the government.
- Schedule II — 12%. The default for most retail-pack medicines under HSN heading 3004. Antibiotics, painkillers, cardiac, diabetic (other than insulin), steroids, antifungals.
- Schedule III — 18%. Mostly excipients, raw materials, and cosmetic preparations. Not many finished retail medicines land here.
The HSN code that almost every medicine carries is 3004 ("medicaments in retail pack"). So the slab assignment isn't a function of the HSN code alone — it's a function of which Schedule the specific drug appeared in when the rate council made its lists in 2017.
For insulin, the rate council very specifically called it out as concessional. The relevant entry in Notification 1/2017 Schedule I reads: "Insulin and insulin analogues". Plain. Both human-derived and biosimilar variants are covered. So Humalog (lispro), Lantus (glargine), Novomix (aspart biphasic), Tresiba (degludec), Mixtard (premixed), and generic insulin all fall in the 5% slab.
Why insulin got the concessional treatment
A few reasons, all worth knowing because they help with the dispute when you're trying to convince a pharmacist:
Insulin is non-substitutable for Type 1 diabetics. A Type 1 patient without insulin will die — there's no alternative therapy. So the policy view is that any consumption tax on insulin is a tax on the patient's right to live. The rate council moved insulin to 5% on essentially the same logic that exempts wheelchairs and concessional rates apply to walking aids.
For Type 2 diabetics, where insulin is one option among many, the same argument is weaker. But the rate council didn't try to draw a line — all insulin formulations get the 5% rate regardless of why the patient is on them.
The rate has held since 2017 across multiple GST Council reviews.
The mistake we see most often
When we audit hospital and pharmacy bills, the wrong-rate-on-insulin pattern shows up consistently. The most common version:
The pharmacy billing system is configured with a default 12% rate on HSN 3004 (the general medicine slab). When a Lantus vial gets scanned at the counter, the system applies the default. The billing clerk doesn't question it because the bill prints "GST 12%" and the customer doesn't question it because Rs 3,000 plus Rs 360 GST feels normal.
The correct figure for that same Lantus vial at MRP Rs 3,000 is Rs 150 GST (5% of base value, not 5% of MRP-inclusive). The pharmacy has collected Rs 210 more than the law allows.
There are a few related variants:
- 12% applied to Humalog Mix 50 (an insulin analogue — should be 5%)
- 12% applied to Tresiba Flextouch (insulin degludec — should be 5%)
- 12% applied to NovoMix 30 Penfill (premixed insulin aspart — should be 5%)
- 12% applied to Insuman Basal vials (human insulin — should be 5%)
In every case the correct figure is 5%. The HSN code on the bill is likely 3004, which is consistent with the 12% default — but the rate council made a specific override for insulin, and the override sits above the default.
How to read it on the bill
Three things to look for:
The HSN code. Look in the line item details for "HSN" or "HSN/SAC". For insulin it will almost always be 3004 or 30043190 (the eight-digit extension). HSN alone doesn't tell you the rate, but it confirms the drug is in the medicaments chapter.
The GST rate. This is usually printed either as a percentage column or as "CGST 6% + SGST 6%". If you see 12% or 6+6 on an insulin line, that's the error. The correct figure is 5% (or 2.5% + 2.5% on a CGST
- SGST split).
The total. The math is GST = base value × rate / 100. If you're paying Rs 3,360 for a vial that's MRP Rs 3,000, the implied GST is Rs 360 on a Rs 3,000 base, which is 12%. If the rate should be 5%, the correct total is Rs 3,150. The Rs 210 difference is what you'd ask back.
What about the hospital inpatient case?
Slightly different. When you're admitted to a hospital and the insulin is given as part of your inpatient treatment, the entire treatment is GST-exempt under Notification 12/2017. The composite supply argument (Servo Packaging and subsequent rulings) extends the healthcare-services exemption to medicines and consumables used during the stay. So inpatient insulin should show Rs 0 GST, not 5%, not 12%.
The 5% rate applies in the outpatient case. A diabetic walks into a hospital pharmacy after a clinic visit, picks up a one-month supply, pays at the counter. Or a retail pharmacy outside a hospital does the same. Those are outpatient sales of goods, and the 5% slab applies.
We've covered the inpatient / outpatient line in more depth in the full GST explainer.
How to ask for a correction
If you spot the 12% rate on an insulin line, the polite ask at the pharmacy counter:
"Could you double-check the GST rate on this insulin? My understanding is that insulin and insulin analogues are notified at 5% under Schedule I of Notification 1/2017 — Central Tax (Rate). The rate on this bill shows 12%."
In our experience the pharmacist either updates the system and re-issues the bill (about half the time), or escalates to their owner who in turn calls their tax consultant. The conversation almost always ends with the bill being corrected.
If the pharmacy refuses, the formal step is to file a complaint with the State GST authority via the GST grievance portal. But honestly, at the pharmacy counter level, the citation is usually enough.
Why we wrote this post
The math we did at the top — Rs 2,500 a year per insulin-using diabetic — is the kind of overcharge that compounds invisibly. A patient never notices Rs 210 on a single bill. But over a career, it adds up to real money that should have stayed with the patient.
Insulin is one of the cleanest cases in Indian tax policy of the government doing the right thing. The 5% concessional rate exists because someone fought for it. Making it actually apply on the bill is on the patient — but the policy is on your side.
Sources: Notification 1/2017 — Central Tax (Rate), Schedule I, entry for insulin and insulin analogues; GST Council circulars on healthcare exemption; CBIC HSN code references for HSN 3004. Informational only; verify against your specific bill and consult a tax professional for binding advice.